Funding

SECTION I: ESTIMATION OF COSTS

1 Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
In this section we expect an analysis of funding needed or expected for valorization of the R&D result. An estimation is expected (range of costs not obviously exact amounts)
… in terms of IPR protection
No costs related to IPR protection are expected.

 

 

 

…in terms of product development
8 persons on translation (30K-40K per year)

2 persons on software development (30K-40K per year)

 

…in terms of mass production
Translation, software development and marketing costs will increase as the demand of the service itself will rise.

 

 

 

 

… in terms of marketing
2 persons active in sales/marketing (30K-40K per year)

 

 

2 Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs
  Year 1 Year 2 Year 3 Year 4 Year 5
Fixed costs 30.000 25.000 20.000 15.000 10.000
Personnel 500.000 600.000 700.000 600.000 500.000
           
Marketing costs 40.000 50.000 60.000 40.000 30.000
TOTAL EXPECTED COSTS 570.000 675.000 790.000 655.000 540.000
Price per Unit 50.000 80.000 120.000 80.000 40.000
Type of Unit MORMED licenses
Number of Units 3 5 8 10 12
TOTAL Expected Revenues 150.000 440.000 960.000 800.000 480.000
CASH FLOW REQUIRED (REVENUES-COSTS) -420.000 -235.000 170.000

 

145.000 -60.000
TOTAL CAPITAL required for five years 3.800.000

 

SECTION 2: QUALITATIVE FACTORS

4 Dimension of identified target groups
An estimation of the proportion of the target market (described in Section 3) which we expect to take
Due to the difficulty of identifying the market’s volume it is not feasible to predict MORMED’s market share.

 

 

 

6 Evaluation of financial Risks for R&D result
MORMED requires significant amount of initial investment capital.

 

 

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

1. European Funding

Define relevance of the product with the following potential funding sources and comment

Note: INTERVALUE partners are expected to pre-define a list of existing European funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. European Research Projects
2 National Funding
Note: INTERVALUE partners are expected to pre-define a list of existing national funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
3 Private funding
Note: INTERVALUE partners are expected to pre-define a list of existing private funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. VCs
4 Other

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
MORMED can offer an interesting translation service, but it requires significant capital making it a risky investment.

 

 

Decision of evaluation (Please tick  as appropriate)

  The R&D has a high potential of exploitation
  The R&D result needs minor revisions
The R&D result needs moderate revisions
  The R&D result needs major revisions
  The R&D result has no potential of exploitation

 

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project